Filing Analysis
Jasper Therapeutics received a deficiency notice from Nasdaq for failing to meet the minimum stockholders' equity requirement of $2.5 million. The company plans to seek stockholder approval to convert Non-Voting Convertible Preferred Stock to regain compliance.
🚩 Red Flags
- Delisting warning (Nasdaq deficiency notice)
- Low stockholders' equity ($2.5M threshold breach)
- Reliance on a complex capital restructuring (preferred stock conversion) to maintain listing
- Uncertainty regarding Nasdaq's acceptance of the proposed compliance plan
📋 Key Facts
- Received Nasdaq deficiency notice on August 21, 2026.
- Failure to meet the $2,500,000 minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1).
- The deficiency is based on stockholders' equity reported in the 10-Q for the period ended June 30, 2026.
- The company has 45 days (until October 5, 2026) to submit a compliance plan.
- Proposed remedy: Seeking stockholder approval for the conversion of outstanding Non-Voting Convertible Preferred Stock.
- If a compliance plan is accepted, the company may receive up to a 180-day extension to regain compliance.
Jasper Therapeutics, Inc. filed an 8-K to report its financial results for the quarter ended June 30, 2026, and provided a corporate update via a press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Filing date: August 14, 2026.
- The filing includes a press release (Exhibit 99.1) containing financial results and a corporate update.
- The report was signed by CFO Herb Cross.
Jasper Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on July 31, 2026. The meeting resulted in the election of two Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on July 31, 2026.
- Quorum represented approximately 75% of voting common stock (21,121,396 shares out of 28,009,802 outstanding).
- Judith Shizuru and Tom Wiggans were elected to the Board of Directors as Class II directors.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- The company is classified as an emerging growth company.
Jasper Therapeutics, Inc. is providing supplemental details regarding its acquisition of Kira Pharmaceuticals, specifically confirming the record date and terms for Contingent Value Rights (CVRs) issued to former Kira shareholders.
🚩 Red Flags
- Contingent liabilities: The company has an outstanding $30 million potential cash outflow contingent on regulatory milestones (Priority Review Voucher).
📋 Key Facts
- The company confirmed the record date for CVR entitlement was July 16, 2026, coinciding with the closing of the Kira acquisition.
- Each share of Common Stock held by Kira shareholders as of the record date is entitled to one (1) CVR.
- Total Milestone Payment pool is $30.0 million.
- The milestone is triggered if the FDA issues a Priority Review Voucher for briquilimab on or before December 31, 2028.
- CVRs are non-transferable and not registered with the SEC.
Jasper Therapeutics, Inc. has entered into a definitive merger agreement to acquire Kira Pharmaceuticals via a merger with a subsidiary. The transaction includes a significant $132 million PIPE financing and the issuance of convertible preferred stock that will result in substantial dilution for existing shareholders.
🚩 Red Flags
- Extreme dilution: Pre-transaction equityholders are diluted from ~11.27% to ~6.68% of the company post-financing.
- Significant convertible securities: The Preferred Stock is highly dilutive, converting at a rate of 1 share into 61 shares of Common Stock.
- Complex capital structure involving CVRs and multiple classes of stock.
📋 Key Facts
- Acquisition of Kira Pharmaceuticals via a merger with Merger Sub (a wholly owned subsidiary).
- Merger consideration includes 5,195,009 shares of Common Stock and 4,644,977 shares of non-voting convertible preferred stock.
- Concurrent $132 million PIPE financing via the sale of approximately 4.7 million shares of Preferred Stock to Investors.
- Post-merger/post-financing ownership structure: Pre-transaction equityholders will hold ~6.68% of Common Stock; Kira former equityholders ~49.86%; and Investors ~43.46%.
- Issuance of Contingent Value Rights (CVR) totaling $30 million, contingent on FDA Priority Review Voucher for briquilimab by Dec 31, 2028.
- Lock-up agreements in place for directors, officers, and Kira shareholders for 180 days.
Jasper Therapeutics, Inc. has completed an all-stock acquisition of Kira Pharmaceuticals and simultaneously secured $132 million in gross proceeds through a private placement financing.
🚩 Red Flags
- All-stock transactions can lead to significant dilution for existing shareholders.
📋 Key Facts
- Completed the acquisition of Kira Pharmaceuticals (a Cayman limited company) via an all-stock transaction.
- Entered into a securities purchase agreement for a private placement financing totaling $132 million in gross proceeds.
- Kira Pharmaceuticals specializes in complement therapies for immune-mediated diseases.
- The filing was signed by CFO Herb Cross on July 16, 2026.
Jasper Therapeutics received a written notice from Nasdaq on June 3, 2026, stating that the company is non-compliant with the minimum bid price requirement of $1.00 per share. The company has until November 30, 2026, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq due to low share price.
- Explicit mention of a potential reverse stock split to cure the deficiency.
📋 Key Facts
- The bid price for voting common stock closed below $1.00 for 30 consecutive business days.
- The company is in violation of Nasdaq Listing Rule 5550(a)(2).
- The deadline to regain compliance is November 30, 2026.
- Compliance requires the bid price to close at $1.00 or more for at least 10 consecutive business days.
- The company explicitly mentioned considering a reverse stock split as a potential remedy.
Jasper Therapeutics announced on June 1, 2026, that its Board of Directors has initiated a comprehensive review of strategic alternatives to maximize shareholder value.
🚩 Red Flags
- A 'strategic alternatives' review in micro-cap companies often signals distress, a search for a buyer due to funding gaps, or a failure of the primary business model.
📋 Key Facts
- The company issued a press release on June 1, 2026, regarding a strategic review.
- The review is intended to maximize shareholder value following an evaluation of current market conditions.
- The announcement was made via a Regulation FD disclosure (Item 7.01).
On May 15, 2026, Christian Nolet resigned from the Board of Directors and all associated committees of Jasper Therapeutics, Inc. The resignation was not due to any disagreement with the company, and Svetlana Lucas, Ph.D., was appointed to the Audit Committee to fill the vacancy.
📋 Key Facts
- Christian Nolet resigned from the Board of Directors and all committees on which he served, effective May 15, 2026.
- The resignation was not due to any disagreement with the Company on any matter relating to operations, policies, or practices.
- Svetlana Lucas, Ph.D., was appointed as a member of the Audit Committee of the Board.
Jasper Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update via a press release.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026.
- The report was filed on May 14, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release was furnished as Exhibit 99.1.
- The company's redeemable warrants (JSPRW) have an exercise price of $115.00 per share, which is significantly higher than standard warrant pricing, often indicating a historical reverse split.
Jasper Therapeutics reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025, and provided a corporate update.
📋 Key Facts
- The filing reports financial results for the fiscal year and quarter ended December 31, 2025.
- The report was filed on March 30, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the detailed financial data and corporate update was furnished as Exhibit 99.1.
- The report was signed by Chief Financial Officer Herb Cross.
Jasper Therapeutics released positive updated clinical data from its BEACON Phase 1b/2a study involving subcutaneous briquilimab for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). The company held a webinar to present these findings.
📋 Key Facts
- Released updated clinical data from the BEACON Phase 1b/2a study of subcutaneous briquilimab.
- Data covers adult participants with chronic spontaneous urticaria (CSU) and an open-label extension in CSU and chronic inducible urticaria (CIndU).
- The announcement included a press release (Exhibit 99.1) and a presentation (Exhibit 99.2).
Jasper Therapeutics, Inc. announced a major leadership transition effective January 5, 2026, involving the departure of CEO Ron Martell and the appointment of COO Jeet Mahal as the new CEO and President.
🚩 Red Flags
- Sudden departure of the CEO and President (even if without cause) can signal internal strategic shifts or friction.
- Significant severance package for departing CEO (18 months salary + COBRA).
📋 Key Facts
- CEO and President Ron Martell will depart effective January 5, 2026; termination is 'without Cause'.
- Ron Martell to receive 18 months of base salary and COBRA premiums subject to a release agreement.
- Jeet Mahal (current COO) appointed as CEO and President and added to the Board as a Class III director.
- Thomas G. Wiggans (current Chairperson) appointed as Executive Chair effective January 5, 2026.
- Mahal's annualized salary increased to $600,000 with an annual performance bonus potential of up to 50%.
Jasper Therapeutics reported positive preliminary clinical data from its ETESIAN Phase 1b asthma study and provided an update regarding the conclusion of an internal investigation into anomalous lack of response in the BEACON CSU study. The company is hosting a webinar to present these findings.
🚩 Red Flags
- Previous 'anomalous lack of clinical response' in July 2025 BEACON study data (cohort 8 and 9) suggests historical volatility/risk in clinical outcomes.
- Clinical-stage biotech risk: Results are preliminary and subject to further validation.
📋 Key Facts
- Reported positive preliminary clinical data from the ETESIAN Phase 1b study (subcutaneous briquilimab) for adult allergic asthma.
- Completed internal investigation into anomalous lack of clinical response observed in July 2025 BEACON data (cohorts 8 and 9).
- Scheduled a conference call/webinar for December 2, 2025, to present ETESIAN data and BEACON investigation findings.
- The filing includes an update on the company's clinical pipeline following previous data anomalies.
Jasper Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025. The filing includes a press release containing corporate updates and financial performance data.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025.
- Filing date: November 10, 2025.
- The report is furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01.
- Includes a press release as Exhibit 99.1.
Jasper Therapeutics announced a $30 million public offering of common stock and warrants to fund clinical development of briquilimab. Simultaneously, the company provided an update on an investigation into anomalous efficacy results in its BEACON study for Chronic Spontaneous Urticaria (CSU).
🚩 Red Flags
- Significant dilution via the issuance of over 11 million new shares and warrants.
- Clinical trial uncertainty: Ongoing investigation into 'anomalous efficacy results' in the BEACON study could impact drug development timelines or regulatory approval prospects.
- The company is raising capital specifically to fund continued clinical programs, indicating a need for cash to maintain operations.
📋 Key Facts
- Public offering of 11,670,707 shares of common stock and accompanying warrants.
- Offering includes up to 675,000 pre-funded warrants with an exercise price of $0.0001.
- Common warrant exercise price is set at $2.92; Common Stock offering price is $2.43 per share (including warrant).
- Gross proceeds expected to be approximately $30.0 million before expenses.
- Proceeds intended for preclinical and clinical development of briquilimab in mast-cell driven diseases.
- Investigation into 'confounded efficacy results' from the BEACON study has ruled out drug substance/product manufacturing issues; focus shifted to clinical site activity (patient selection, administration, etc.).
- Expected closing date: on or about September 22, 2025.
Jasper Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025, and provided a corporate update via press release.
📋 Key Facts
- Reporting date: August 13, 2025
- Financial results reported are for the quarter ended June 30, 2025
- The filing includes a corporate update alongside financial results
- Information is furnished under Item 2.02 and Item 9.01 of Form 8-K
Jasper Therapeutics is undergoing a major corporate reorganization to extend its cash runway, which includes a 50% workforce reduction and the termination of several clinical/preclinical programs. The company will focus exclusively on its briquilimab development program for chronic urticaria.
🚩 Red Flags
- Significant workforce reduction (50%) indicates severe liquidity/cash runway constraints.
- Abandonment of multiple clinical and preclinical programs suggests a pivot due to capital exhaustion.
- Departure of the Chief Medical Officer (CMO) during a major strategic pivot.
📋 Key Facts
- Workforce reduction of approximately 50%.
- Halting all non-briquilimab clinical and preclinical programs.
- Estimated reorganization costs (severance) between $1.8 million and $2.2 million through Q3 2025.
- Chief Medical Officer Dr. Edwin Tucker will depart effective August 1, 2025, via termination without cause.
- Dr. Tucker to receive 12 months of base salary and COBRA premiums upon execution of a release.
Jasper Therapeutics, Inc. issued an 8-K to announce the release of updated clinical data from its BEACON Phase 1b/2a study regarding subcutaneous briquilimab for chronic spontaneous urticaria.
📋 Key Facts
- The filing pertains to updated data from the BEACON Phase 1b/2a study.
- The study involves subcutaneous briquilimab in adult participants with chronic spontaneous urticaria.
- The company held a conference call and webinar on July 7, 2025, to present the clinical updates.
- Exhibits include a press release (99.1) and a corporate presentation (99.2).
Jasper Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders on July 3, 2025. The meeting resulted in the election of three Class I directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on July 3, 2025.
- Approximately 80% of voting common stock (12,014,527 shares) were represented via proxy or virtually.
- Three Class I directors elected: Kurt von Emster, Scott Brun, M.D., and Vishal Kapoor.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal year ending Dec 31, 2025.
- Stockholders approved advisory votes on executive compensation frequency to be held every one year.
Jasper Therapeutics announced positive clinical data from the 180mg cohort of its SPOTLIGHT Phase 1b/2a study for subcutaneous briquilimab in treating chronic inducible urticaria. The company scheduled a presentation and webinar to discuss these results.
📋 Key Facts
- Positive data reported from the 180mg cohort of the SPOTLIGHT Phase 1b/2a study.
- The study involves subcutaneous briquilimab for adult participants with chronic inducible urticaria.
- Company scheduled a conference call and webinar for June 16, 2025, to present detailed data.
Jasper Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025, and provided a general corporate update via a press release.
📋 Key Facts
- Reporting date: May 12, 2025
- Financial results reported for the quarter ended March 31, 2025
- The filing includes a press release as Exhibit 99.1 providing corporate updates
- Company is classified as an emerging growth company
Jasper Therapeutics entered into a new $100 million Open Market Sale Agreement (ATM offering) with Jefferies LLC and simultaneously terminated its previous sales agreement with Cantor Fitzgerald & Co.
🚩 Red Flags
- Potential dilution for existing shareholders via the $100M ATM offering.
- Frequent switching of sales agents (Cantor to Jefferies) can sometimes indicate a search for better market terms or liquidity needs.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on March 19, 2025.
- The new offering allows for the sale of common stock up to an aggregate price of $100,000,000.
- Jefferies LLC will receive a 3.0% compensation fee on gross sales.
- Terminated the previous Cantor Sales Agreement effective March 14, 2025; no material penalties were incurred.
- The company has not sold any shares under the terminated Cantor agreement since November 10, 2022.
Jasper Therapeutics, Inc. filed an 8-K to furnish its quarterly and fiscal year results for the period ended December 31, 2024, alongside a corporate update via press release.
📋 Key Facts
- Reporting of financial results for the quarter and fiscal year ended December 31, 2024.
- Release of a general corporate update as of February 27, 2025.
- The company is classified as an 'emerging growth company'.
- Information was furnished under Item 2.02 and Item 9.01.
Jasper Therapeutics announced positive preliminary data from its BEACON Phase 1b/2a study of subcutaneous briquilimab for treating chronic spontaneous urticaria. The company held a conference call and webinar to present these results.
📋 Key Facts
- Reported positive preliminary data from the BEACON Phase 1b/2a study.
- The study evaluates subcutaneous briquilimab in adult participants with chronic spontaneous urticaria.
- Data was presented via a conference call and webinar on January 8, 2025.
Jasper Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024, and a corporate update via press release.
📋 Key Facts
- Reporting of financial results for the quarter ended September 30, 2024.
- Issuance of a corporate update alongside the earnings release.
- The filing is furnished under Item 2.02 and not 'filed' for purposes of Section 18 liability.
Jasper Therapeutics, Inc. issued an 8-K to report positive clinical data from its ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab for treating cold urticaria or symptomatic dermographism.
📋 Key Facts
- Reported positive data from the SPOTLIGHT Phase 1b/2a study.
- The study evaluates subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism.
- Filing date: October 15, 2024; Event date: October 14, 2024.
Jasper Therapeutics, Inc. announced the resignation of Dr. Anna French from its Board of Directors and the simultaneous appointment of Dr. Svetlana Lucas as a Class III director.
🚩 Red Flags
- None identified; the departure of Dr. French was explicitly stated to be non-dispute related.
📋 Key Facts
- Dr. Anna French resigned from the Board effective June 18, 2024; her departure was not due to any disagreement with the Company.
- Svetlana Lucas, Ph.D., appointed to the Board as a Class III director on June 18, 2024.
- Dr. Lucas is currently the Chief Business Officer at Scribe Therapeutics Inc. and has extensive experience at Amgen and Tizona Therapeutics.
- Dr. Lucas was granted an option to purchase 15,000 shares of common stock with an exercise price of $23.19 per share.
- The stock option for the new director follows a standard vesting schedule: 25% after one year, and the remainder in monthly increments over 48 months.
Jasper Therapeutics held its 2024 Annual Meeting of Stockholders where shareholders approved the 2024 Equity Incentive Plan and Employee Stock Purchase Plan. The company also entered into amended and restated employment agreements with several key executives, including the CEO, CFO, COO, and CMO.
🚩 Red Flags
- Termination of a general severance plan in favor of individualized executive agreements can sometimes indicate increased fixed liabilities or potential friction, though common in restructuring/growth phases.
📋 Key Facts
- Annual Meeting held on June 6, 2024; 82.6% of voting common stock represented (12,454,542 shares).
- Stockholders approved the 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan.
- Amended and Restated Employment Agreement entered with CEO Ronald Martell; includes a change-in-control severance of 18 months salary plus 1.5x target bonus.
- Amended and Restated Employment Agreements entered with CFO Herb Cross, COO Jeet Mahal, and CMO Edwin Tucker.
- The Company terminated its general Employee Severance Plan for Vice Presidents and Executive Committee Members in favor of individual agreements.
Jasper Therapeutics, Inc. filed an 8-K to announce its financial results for the fiscal quarter and year ended December 31, 2023. The filing serves as a formal announcement of recent corporate developments and quarterly earnings.
📋 Key Facts
- Reporting period: Fiscal quarter and year ended December 31, 2023.
- Filing date: March 4, 2024.
- The company is an emerging growth company.
- Information was furnished under Item 2.02 and Item 9.01 of Form 8-K.
Jasper Therapeutics, Inc. entered into an underwriting agreement to conduct a public offering of 3,900,000 shares of common stock at $12.95 per share. The company expects gross proceeds of approximately $50 million to fund clinical development programs for briquilimab.
🚩 Red Flags
- Dilution risk for existing shareholders due to the issuance of 3.9 million new shares.
📋 Key Facts
- Underwriting agreement entered into on February 6, 2024, with Cowen and Company, LLC and Evercore Group L.L.C.
- Offering size: 3,900,000 shares of voting common stock.
- Offering price: $12.95 per share; Underwriters' purchase price: $12.17 per share.
- Estimated gross proceeds: approximately $50 million (before expenses).
- Expected closing date: on or about February 8, 2024.
- Use of proceeds: advancement of preclinical and clinical development programs for briquilimab in mast-cell driven diseases (chronic spontaneous urticaria and chronic inducible urticaria), capital expenditures, working capital, and G&A expenses.
- Lock-up period: Directors and executive officers are subject to a lock-up until May 7, 2024.
Jasper Therapeutics, Inc. has implemented a 1-for-10 reverse stock split effective January 4, 2024. The action was taken to regain compliance with the Nasdaq minimum bid price requirement of $1.00 per share.
🚩 Red Flags
- Reverse stock split executed to avoid Nasdaq delisting due to non-compliance with minimum bid price requirements ($1.00/share).
- Indicates significant downward pressure on share price prior to the split.
📋 Key Facts
- The company executed a 1-for-10 reverse stock split on January 3, 2024.
- Every ten (10) shares of pre-split Common Stock were combined into one (1) share of post-split Common Stock.
- The split is effective as of 12:01 a.m. ET on January 4, 2024.
- Warrants (JSPRW) will be adjusted such that every 10 warrants are exercisable for one share at an increased exercise price of $115.00 per share.
- Fractional shares will be settled in cash based on the closing sales price from January 3, 2024.
Jasper Therapeutics, Inc. issued a press release regarding a pending reverse stock split of its voting common stock. This filing is primarily used to furnish the press release under Item 7.01.
🚩 Red Flags
- Pending reverse stock split: Often used by micro-cap/biotech companies to boost share price to meet minimum exchange listing requirements (Nasdaq).
📋 Key Facts
- Company announced a pending reverse split of its voting common stock via press release dated January 2, 2024.
- The announcement was made pursuant to Item 7.01 (Regulation FD Disclosure).
- The filing includes Exhibit 99.1 containing the specific details of the reverse split.